All times shown are PDT (GMT-7) (San Francisco)
Displaying One Session
Abstract Sessions On-Demand Channel
Oral poster discussion session
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Introduction
Session Name
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Time to viral rebound after interruption of modern antiretroviral therapies
Session Name
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Is DTG+3TC effective and safe in clinical practice? Evidence from real world data
Speaker
Session Name
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis
Session Name
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR)
Session Name
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Optimizing the management of patients with virologic non-suppression
Session Name
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session
Conclusion
Session Name
Room
Abstract Sessions On-Demand Channel